Best of ASCO - 2014 Annual Meeting

 

Welcome

Hepatobiliary Cancer

Gastrointestinal (Noncolorectal) Cancer

2018 ASCO Annual Meeting

Sort by: title abstract no. first author
ABSTRACT TITLEFIRST AUTHORABSTRACT NO.
A bi-institutional phase II study of hepatic arterial infusion (HAI) with floxuridine (FUDR) and dexamethasone (Dex) combined with systemic gemcitabine and oxaliplatin (GemOx) for unresectable intrahepatic cholangiocarcinoma (ICC).

Andrea Cercek

4092

A first-in-human phase I study of sEphB4-HSA (sEphB4) with expansion in hepatocellular (HCC) and cholangiocarcinoma (CCA).

Jacob Stephen Thomas

e16136

A multicenter phase Ib-IIR trial assessing the activity of regorafenib combined with modified gemcitabine: Oxaliplatin (mGEMOX) in patients with advanced biliary tract cancer (aBTC).

Eric Assenat

e16134

A multicenter pilot study of nivolumab (NIVO) with drug eluting bead transarterial chemoembolization (deb-TACE) in patients (pts) with liver limited hepatocellular carcinoma (HCC).

James J. Harding

TPS4146

A multi-center randomized phase II study of nivolumab in combination with gemcitabine/cisplatin or ipilimumab as first line therapy for patients with advanced unresectable biliary tract cancer.

Vaibhav Sahai

TPS4142

A multicenter, single arm phase II trial of a small molecule immune-modulator icaritin: Safety, overall survival, immune dynamics, and PD-L1 expression in advanced hepatocellular carcinoma.

Yan Sun

4077

A new prediction model for prognosis of patients with intermediate HCC after conventional transarterial chemoembolization.

Rong-xin Chen

e16128

A novel prognostic classifier for intrahepatic cholangiocarcinoma: Development and external and prospective validation studies.

Guang-Zhi Jin

e16102

A phase 1b trial of lenvatinib (LEN) plus pembrolizumab (PEM) in patients (pts) with unresectable hepatocellular carcinoma (uHCC).

Masafumi Ikeda

4076

A phase II study of ramucirumab for advanced, pre-treated biliary cancers.

Jonathan Mizrahi

4081

A randomized, multicenter phase 3 study of durvalumab (D) and tremelimumab (T) as first-line treatment in patients with unresectable hepatocellular carcinoma (HCC): HIMALAYA study.

Ghassan K. Abou-Alfa

TPS4144

ADI-PEG 20 and FOLFOX6: A phase 1 study in pts (pts) with advanced hepatocellular carcinoma (HCC).

James J. Harding

4085

Analysis of prognostic factors for gallbladder cancer (GBC) of patients assisted in an academic hospital in Chile.

Luis Villanueva

e16127

Anti-programmed death-1 antibody SHR-1210 (S) combined with apatinib (A) for advanced hepatocellular carcinoma (HCC), gastric cancer (GC) or esophagogastric junction (EGJ) cancer refractory to standard therapy: A phase 1 trial.

Jian-Ming Xu

4075

Apatinib administration following transcatheter arterial chemoembolization for hepatocellular carcinoma with pulmonary metastasis: A single-institutional experience.

Guoliang Shao

e16104

Assessing clinical outcomes following liver transplantation in intrahepatic cholangiocarcinoma and mixed hepatocellular carcinoma-cholangiocarcinoma patients: The Mayo Clinic experience.

Thomas DeLeon

e16114

Association between hospital volume, treatment patterns and overall survival (OS) of patients with intrahepatic cholangiocarcinoma (IHCC).

Sri Harsha Tella

e16118

Association of immune biomarkers with overall and disease-free survival in hepatocellular carcinoma.

Qiyun Ou

e16129

Cabozantinib (C) versus placebo (P) in patients (pts) with advanced hepatocellular carcinoma (HCC) who have received prior sorafenib: Results from the randomized phase 3 CELESTIAL trial.

Ghassan K. Abou-Alfa

4019

CD13-HDAC5 signaling axis promotes hepatocecullar carcinoma and sorafenib resistance by activating NF-KB.

Xin-Rong Yang

e16144

Clinical and prognostic significance of serum levels of angiopoietin-1 (sAng-1) and angiopoietin-2 (sAng-2) in hepatocellular carcinoma (HCC).

Roberto Carmagnani Pestana

e16152

Combination of local ablation and chemotherapy for intrahepatic cholangiocarcinoma: Survival trends from the National Cancer Database.

Johannes Uhlig

e16150

Correlation of overall survival (OS) in patients (pts) with inoperable hepatocellular carcinoma (iHCC) receiving tivozanib (TIVO) with baseline performance status.

Sunyoung S. Lee

e16122

Detection of early recurrence in HCC patients after TACE treatment with plasma cfDNA.

Xiao Du

e16146

Development and validation of nomograms to provide individualized predictions of survival benefits from surgery in patients with intermediate/advanced hepatocellular carcinoma.

Xin-Fei Xu

e16112

Efficacy and safety of apatinib in refractory unresectable and metastatic cholangiocarcinoma: A retrospective analysis.

Haibo Mou

e16123

Exploratory analyses of the BILCAP study.

John A. Bridgewater

e16132

Genomic diversity between Asian and United States intrahepatic cholangiocarcinoma patients.

Reham Abdel-Wahab

e16137

Genotyping of circulating tumor DNA in biliary tract cancer reveals diagnostic and prognostic information.

Andreas Wolfgang Berger

e16147

IMbrave150: A randomized phase III study of 1L atezolizumab plus bevacizumab vs sorafenib in locally advanced or metastatic hepatocellular carcinoma.

Richard S. Finn

TPS4141

Impact of cholangiocarcinoma (CC) molecular heterogeneity on outcome during first-line chemotherapy and access to targeted therapies in early clinical trials (CT).

Helena Verdaguer

4091

Impact of sex on outcomes and adverse events in the advanced biliary tract cancer (ABC)-01 to -04 studies.

John A. Bridgewater

e16131

Impact of sex on toxicity and outcome in the BILCAP study.

Richard Fox

e16151

Impact of surveillance on long-term outcomes after curative liver resection for hepatocellular carcinoma: Analysis of 1,075 patients with chronic hepatitis B infection from a prospective database over 12 years.

Jiong-Jie Yu

e16109

Incretin based drugs and the risk of cholangiocarcinoma in patients with type 2 diabetes.

Devin Abrahami

e16126

Initial experience of combination nivolumab and local-regional treatment in patients with advanced hepatocellular carcinoma (HCC).

Ping Gu

e16149

Is surgical resection justified for hepatocellular carcinoma with portal vein tumor thrombus? A systematic review and meta-analysis.

Li-Yang Sun

e16111

Liposomal irinotecan (nal-IRI) plus 5-fluorouracil (5-FU) and leucovorin (LV) or gemcitabine plus cisplatin in advanced cholangiocarcinoma: The AIO-NIFE-trial, an open label, randomized, multicenter phase II trial.

Thomas Jens Ettrich

TPS4145

Multi institutional phase II trial of single agent regorafenib in refractory advanced biliary cancers.

Richard D. Kim

4082

NAP-CAPABIL: Pilot study of NAB-paclitaxel in combination with capecitabine as second line treatment of advanced biliary cancer.

Morteza Aghmesheh

e16156

Oncologic effectiveness of transarterial chemoembolization in local control of large hepatocellular carcinoma.

Jason M. Low

e16148

Outcomes based on age in the phase 3 CELESTIAL trial of cabozantinib (C) versus placebo (P) in patients (pts) with advanced hepatocellular carcinoma (HCC).

Lorenza Rimassa

4090

Outcomes in patients (pts) who had received sorafenib (S) as the only prior systemic therapy in the phase 3 CELESTIAL trial of cabozantinib (C) versus placebo (P) in advanced hepatocellular carcinoma (HCC).

Robin Kate Kelley

4088

Outcomes of patients (pts) with hepatocellular carcinoma (HCC) treated with transarterial chemoembolization (TACE): Global OPTIMIS final analysis.

Markus Peck-Radosavljevic

4018

Pembrolizumab (pembro) in patients with advanced hepatocellular carcinoma (HCC): KEYNOTE-224 update.

Andrew X. Zhu

4020

Perioperative outcomes in elderly patients undergoing hepatic resection for hepatocellular carcinoma: A systematic review and meta-analysis.

Elinor Tan

e16130

Phase 1B study of enzalutamide (ENZA) with or without sorafenib (SORA) in patients (pts) with advanced hepatocellular carcinoma (HCC).

James J. Harding

4083

Phase 2 trial of pembrolizumab (PEM) plus granulocyte macrophage colony stimulating factor (GM-CSF) in advanced biliary cancers (ABC): Clinical outcomes and biomarker analyses.

Robin Kate Kelley

4087

Phase I dose-finding study of OPB-111077, a novel STAT3 inhibitor, in patients with advanced hepatocellular carcinoma.

Changhoon Yoo

4078

Phase Ib study of binimetinib (MEK162) in combination with capecitabine in gemcitabine-pretreated advanced biliary tract cancer.

Jin Won Kim

4079

Phase II study of pembrolizumab in advanced, unresectable hepatocellular carcinoma.

Lynn G. Feun

4086

Phase II trial of sorafenib plus doxorubicin (SD) in patients (Pts) with advanced hepatocellular carcinoma (HCC) after progression of disease (PD) on sorafenib (S).

Imane H. El Dika

4080

Platelet count at baseline (Plt) and outcomes in patients (pts) with advanced hepatocellular carcinoma (HCC) treated with sorafenib (S) in CALGB80802 (Alliance) (C8).

Ghassan K. Abou-Alfa

e16107

Prediction of overall survival with 2nd-line (L2OS) chemotherapy (CT) in patients (Pts) with advanced biliary tract cancer (aBTC): AGEO CT2BIL cohort update and international multicenter external validations.

Cindy Neuzillet

e16119

Preoperative prealbumin level as an independent predictor of long-term outcomes after hepatectomy of hepatocellular carcinoma: A multi-institution study of 1,483 patients.

Ju-Dong Li

e16110

Prognostic significance of neutrophil-to-lymphocyte ratio in racial minorities with hepatocellular carcinoma.

Santiago Thibaud

e16154

Prognostic significance of periostin in patients with hepatocellular carcinoma.

Ahmed Omar Kaseb

e16143

Randomized phase III study of gemcitabine plus S-1 combination therapy versus gemcitabine plus cisplatin combination therapy in advanced biliary tract cancer: A Japan Clinical Oncology Group study (JCOG1113, FUGA-BT).

Makoto Ueno

4014

Randomized, open label, multicenter, phase II trial of transcatheter arterial chemoembolization (TACE) therapy in combination with sorafenib as compared with TACE alone in patients with hepatocellular carcinoma: TACTICS trial.

Masatoshi Kudo

4017

REACH-2: A randomized, double-blind, placebo-controlled phase 3 study of ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma (HCC) and elevated baseline alpha-fetoprotein (AFP) following first-line sorafenib.

Andrew X. Zhu

4003

Real-time circulating tumor DNA profiling of advanced cholangiocarcinoma (CCA).

Kabir Mody

4089

Risk factors, patterns, and outcomes of late recurrence after liver resection for hepatocellular carcinoma: A multicenter cohort study in 734 patients over 15 years.

Xin-Fei Xu

e16108

Safety and clinical activity of 1L atezolizumab + bevacizumab in a phase Ib study in hepatocellular carcinoma (HCC).

Stacey Stein

4074

Selumetinib (Sel) and cisplatin/gemcitabine (CisGem) for advanced biliary tract cancer (BTC): A randomized trial.

Mark Doherty

4084

The efficacy of adjuvant interferon, tumor vaccines and cellular immunotherapies in hepatocellular carcinoma.

Qiyun Ou

e16125

The risk of developing hepatocellular carcinoma following non-Hodgkin lymphoma.

Mahmoud Chaker

e16141

The safety and efficacy of hepatic arterial infusion chemotherapy with cisplatin.

Kazuhiro Matsumoto

e16116

Transarterial chemoembolization treatment in the management of BCLC c stage hepatocellular carcinoma: A large real-world observational study of 885 cases.

Xin Yin

e16115

Treatment patterns and survival for hepatocellular carcinoma in USA and Taiwan.

Shi-Yi Wang

e16120

TREETOPP: A phase 2/3 study of varlitinib plus capecitabine versus placebo plus capecitabine as second-line treatment in patients with advanced or metastatic biliary tract cancers (BTCs).

Milind M. Javle

TPS4143

Understanding quality of life in hepatocellular carcinoma patients.

Stacie Hudgens

4093

Unresectable hepatocellular carcinoma treated with lenvatinib or sorafenib: A disease modeling study.

Gabriel Tremblay

e16157

Utility of Neuropilin-1 in predicting survival in patients with hepatocellular carcinoma.

Yehia I. Abugabal

e16142